AU Patent

AU2022208641A1 — Solid forms of alpha-1062 gluconate

Assigned to Alpha Cognition Inc · Expires 2023-08-03 · 3y expired

What this patent protects

The invention relates to crystalline forms of Alpha-1062 gluconate (scheme I: (I)). In one aspect, the invention relates to a crystalline solid form of Alpha-1062 gluconate (Form A), wherein said crystalline form has prominent peaks at 3.61, 10.98, 14.41 and 18.44 degrees 2-theta…

USPTO Abstract

The invention relates to crystalline forms of Alpha-1062 gluconate (scheme I: (I)). In one aspect, the invention relates to a crystalline solid form of Alpha-1062 gluconate (Form A), wherein said crystalline form has prominent peaks at 3.61, 10.98, 14.41 and 18.44 degrees 2-theta (± 0.2) in a powder X-ray diffraction pattern. The invention further relates to methods, for manufacturing crystalline forms and compositions comprising said crystalline forms.

Drugs covered by this patent

Patent Metadata

Patent number
AU2022208641A1
Jurisdiction
AU
Classification
—
Expires
2023-08-03
Drug substance claim
No
Drug product claim
No
Assignee
Alpha Cognition Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.